Effect of sodium nitroprusside on complement activation induced by cardiopulmonary bypass: a clinical and experimental study

The Journal of Thoracic and Cardiovascular Surgery
M C SeghayeG von Bernuth

Abstract

Complement activation and leukocyte stimulation were prospectively studied during and after cardiopulmonary bypass in 16 children receiving sodium nitroprusside--a nitrovasodilator releasing nitric oxide--for vasodilation during the cooling and rewarming periods of extracorporeal circulation. Results were compared with those in 29 patients who were not treated with sodium nitroprusside during the operation. Patients treated with sodium nitroprusside had significantly less C3 conversion during cardiopulmonary bypass as measured by the ratio C3d/C3 (p <0.05) and significantly less C5a liberation immediately after cardiopulmonary bypass (p < 0.005) than patients not treated with sodium nitroprusside. C4 was not overtly consumed in our series. Leukocyte count during the rewarming period of cardiopulmonary bypass, but not leukocyte elastase release during cardiopulmonary bypass, was significantly reduced in patients treated with sodium nitroprusside (p <0.05). In vitro experiments were conducted to analyze the effect of sodium nitroprusside on complement hemolytic activity initiated by the classic and the alternate pathways and on zymosan-induced C3 conversion by the activation of the alternate pathway. The in vitro experiments clea...Continue Reading

References

Feb 6, 1975·The New England Journal of Medicine·R F Palmer, K C Lasseter
Oct 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·T D OuryJ D Crapo
Jun 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·P KubesD N Granger
Jan 1, 1991·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·N J JansenC R Wildevuur
Nov 1, 1990·Clinical Immunology and Immunopathology·W ScholzE L Morgan
Dec 1, 1987·The Annals of Thoracic Surgery·W van OeverenC R Wildevuur
Oct 1, 1989·Journal of Cardiothoracic Anesthesia·L W AndersenJ P Rasmussen
Dec 1, 1983·The Journal of Thoracic and Cardiovascular Surgery·J K KirklinA D Pacifico
Jul 2, 1981·The New England Journal of Medicine·J V White
Feb 26, 1981·The New England Journal of Medicine·D E ChenowethJ W Kirklin
Dec 30, 1993·The New England Journal of Medicine·S Moncada, A Higgs
Jul 1, 1993·The Journal of Thoracic and Cardiovascular Surgery·Y T WachtfogelL H Edmunds
May 14, 1994·Lancet·E Anggård
Jul 1, 1994·The Journal of Surgical Research·H AbdihD J Bouchier-Hayes
Dec 1, 1993·The Journal of Thoracic and Cardiovascular Surgery·M C SeghayeG von Bernuth
Jan 1, 1993·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·N E MoatT W Evans
Feb 1, 1993·The Annals of Thoracic Surgery·J ButlerS Westaby
May 1, 1993·Circulation·D G Harrison, J N Bates

❮ Previous
Next ❯

Citations

Mar 28, 2001·The Annals of Thoracic Surgery·M SiglerM C Seghaye
Feb 21, 2002·Journal of Cardiothoracic and Vascular Anesthesia·Richard I Hall
Jan 28, 2014·Scandinavian Cardiovascular Journal : SCJ·Vilyam MelkiJan W Borowiec
Mar 5, 2011·Cytometry. Part B, Clinical Cytometry·Jozsef BocsiAttila Tárnok
Aug 24, 1999·Perfusion·G Asimakopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.